Pyxis Oncology (PYXS) Cash from Investing Activities (2021 - 2025)
Pyxis Oncology (PYXS) reported Cash from Investing Activities of $16.3 million for Q4 2025, down 39.0% year-over-year from $26.7 million in Q4 2024, and up 41.76% on a QoQ basis from $11.5 million in Q3 2025.
Pyxis Oncology (PYXS) has 5 years of Cash from Investing Activities data on file, last reported at $16.3 million in Q4 2025.
- Quarterly Cash from Investing Activities fell 39.0% year-over-year to $16.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $58.9 million (up 621.73% YoY) and the FY2025 annual result came in at $58.9 million, up 621.73% from the prior year.
- Cash from Investing Activities climbed to $16.3 million in Q4 2025 per PYXS's latest filing, from $11.5 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $26.7 million in Q4 2024 and bottomed at -$99.4 million in Q1 2023.
- The 5-year median for Cash from Investing Activities is -$68500.0 (2022), against an average of -$2.5 million.
- The widest annual swing landed in 2023, when Cash from Investing Activities tumbled 67977.4%; it then soared 382500.0% in 2025.
- Tracing PYXS's Cash from Investing Activities over 5 years: stood at -$371000.0 in 2021, then plunged by 400.81% to -$1.9 million in 2022, then soared by 650.48% to $10.2 million in 2023, then soared by 160.63% to $26.7 million in 2024, then sank by 39.0% to $16.3 million in 2025.
- Per Business Quant, the three latest PYXS Cash from Investing Activities figures stand at $16.3 million (Q4 2025), $11.5 million (Q3 2025), and $15.3 million (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | -2.89 Mn |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | 638.50 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | -431.90 Mn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | -428.90 Mn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | -25.54 Mn |
| 10 | Pyxis Oncology | 120.87 Mn | 103.97 Mn | 8.65 Mn | 16.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 16.26 Mn |
| Dec 31, 2025 | 16.26 Mn |
| Sep 30, 2025 | 11.47 Mn |
| Sep 30, 2025 | 11.47 Mn |
| Jun 30, 2025 | 15.30 Mn |
| Jun 30, 2025 | 15.30 Mn |
| Mar 31, 2025 | 15.82 Mn |
| Mar 31, 2025 | 15.82 Mn |
| Dec 31, 2024 | 26.66 Mn |
| Dec 31, 2024 | 26.66 Mn |
| Sep 30, 2024 | -8,000.00 |
| Sep 30, 2024 | -8,000.00 |
| Jun 30, 2024 | 4,000.00 |
| Jun 30, 2024 | 4,000.00 |
| Mar 31, 2024 | -18.50 Mn |
| Mar 31, 2024 | -18.50 Mn |
| Dec 31, 2023 | 10.23 Mn |
| Dec 31, 2023 | 10.23 Mn |
| Sep 30, 2023 | 6.57 Mn |
| Sep 30, 2023 | 6.57 Mn |
| Jun 30, 2023 | -22.26 Mn |
| Jun 30, 2023 | -22.26 Mn |
| Mar 31, 2023 | -99.39 Mn |
| Mar 31, 2023 | -99.39 Mn |
| Dec 31, 2022 | -1.86 Mn |
| Dec 31, 2022 | -1.86 Mn |
| Sep 30, 2022 | -4.27 Mn |
| Sep 30, 2022 | -4.27 Mn |
| Jun 30, 2022 | -129,000.00 |
| Jun 30, 2022 | -129,000.00 |
| Mar 31, 2022 | -146,000.00 |
| Mar 31, 2022 | -146,000.00 |
| Jun 30, 2021 | -371,000.00 |
| Jun 30, 2021 | -371,000.00 |
| Mar 31, 2021 | -219,000.00 |
| Mar 31, 2021 | -219,000.00 |